HC Wainwright Lowers Alumis (NASDAQ:ALMS) Price Target to $14.00

Alumis (NASDAQ:ALMS - Get Free Report) had its target price decreased by investment analysts at HC Wainwright from $15.00 to $14.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's target price indicates a potential upside of 235.25% from the company's current price. HC Wainwright also issued estimates for Alumis' Q1 2025 earnings at ($1.03) EPS, Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.74) EPS and FY2025 earnings at ($3.22) EPS.

Several other research firms also recently commented on ALMS. Cantor Fitzgerald reiterated an "overweight" rating on shares of Alumis in a research note on Thursday, March 20th. Oppenheimer started coverage on Alumis in a report on Thursday, January 30th. They issued an "outperform" rating and a $32.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Alumis presently has a consensus rating of "Buy" and an average target price of $25.86.

Alumis Stock Performance

Alumis stock traded down $0.13 during trading hours on Tuesday, reaching $4.18. The stock had a trading volume of 33,004 shares, compared to its average volume of 316,598. Alumis has a 52 week low of $3.18 and a 52 week high of $13.53. The business's 50 day moving average price is $5.52 and its 200-day moving average price is $7.72.

Insider Buying and Selling at Alumis

In related news, CEO Martin Babler bought 15,650 shares of the stock in a transaction dated Tuesday, April 1st. The stock was acquired at an average price of $6.44 per share, for a total transaction of $100,786.00. Following the acquisition, the chief executive officer now owns 106,454 shares in the company, valued at approximately $685,563.76. This represents a 17.23 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Alan Colowick bought 16,104 shares of the stock in a transaction dated Tuesday, April 1st. The shares were acquired at an average price of $6.97 per share, for a total transaction of $112,244.88. Following the completion of the transaction, the director now owns 16,104 shares of the company's stock, valued at approximately $112,244.88. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here.

Institutional Investors Weigh In On Alumis

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC acquired a new stake in shares of Alumis during the third quarter valued at $3,266,000. State Street Corp acquired a new position in shares of Alumis in the 3rd quarter valued at about $866,000. Stifel Financial Corp purchased a new stake in Alumis during the third quarter worth approximately $931,000. Barclays PLC acquired a new stake in Alumis in the 3rd quarter valued at $197,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Alumis by 4.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 113,401 shares of the company's stock valued at $891,000 after buying an additional 4,808 shares during the period.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.